CROs (Contract Research Organization) are contracted, in this case, so a small biotech like CytoDyn doesn't have to maintain a large staff to run trials in-house from conception to approval.
Yes, CytoDyn has had Chief Medical Officers and other members of the management team that will play a role but, trials are "farmed out: to the CRO on a contractual basis to essentially cover every aspect of the trial. It appears (and I'm sure we'll find out more) CytoDyn was relying on the self-proclaimed expertise of Amarex to get their trials from conception to approval - except we've gotten no approvals. Amarex has some ownership of the design flaws, data problems, and reporting problems (BLA) we've seen with many of the trials. They brag about their successes:
Years
20+ Years
Trials
400+ Trials
Patients
85000+ Patients
Ide
125+ IND/IDE/510(k)s
Approvals
25 Approvals
***
I guess the results resulting from Amarex's work on behalf of CytoDyn won't be part of Amarex's advertising campaign.
IMO
Market Data 
Markets 
AI
